Inadequate bowel prep due to side effects of Ozempic and Mounjaro carries significant risk of missed lesions, canceled procedures and other complications.
Side effects of Ozempic and similar GLP-1 drugs approved for treatment of diabetes and weight loss can delay gastric emptying and increase the risk of aspiration during upper GI endoscopic procedures.
Patients with eating disorders taking Wegovy and Zepbound may end up taking too much of the drugs, or experience other severe side effects.
Awareness of Ozempic and Wegovy side effects may be driving more younger patients to report adverse events linked to the drugs, researchers speculate.
Doctors should discuss with patients the risks of aspiration during sedation due to Ozempic, Mounjaro stomach paralysis side effects, letter indicates.
The risk of Ozempic and Wegovy vision changes were seven times higher than for patients who took non-semaglutide drugs for diabetes and weight loss.
A combination of both GLP-1 medications and exercise were needed to achieve weight loss without also losing bone density, researchers found.
Researchers say the sudden metabolic and caloric weight loss caused by Ozempic, combined with direct effects the drug has on brain functions may cause impulse control disorders.
Findings align with warnings issued by anesthesiologists last summer about Ozempic aspiration risks, following reports of life-threatening problems caused by delayed gastric emptying during surgery.
Death reports linked to Ozempic and similar drugs indicate users suffered from intestinal masses, stomach paralysis, pancreatic cancer and seizures.
